This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Signal Transduction and Targeted Therapy Open Access 13 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Dudek, M. et al. Auto-aggressive CXCR6 + CD8 T cells cause liver immune pathology in NASH. Nature 592, 444–449 (2021)
Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature https://doi.org/10.1038/s41586-021-03362-0 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. T cells in NASH and liver cancer: pathology and immunotherapy. Nat Rev Gastroenterol Hepatol 18, 367 (2021). https://doi.org/10.1038/s41575-021-00461-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-021-00461-1
This article is cited by
-
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Signal Transduction and Targeted Therapy (2022)